Avmapki Fakzynja Co‑Pack in Bangladesh
How patients in Bangladesh access Avmapki Fakzynja Co‑Pack (vemurafenib + cobimetinib) via Named Patient Program.
Avmapki Fakzynja Co‑Pack - overview
Avmapki Fakzynja Co‑Pack (vemurafenib + cobimetinib) is manufactured by Genentech / Roche (verify co-pack) and indicated for BRAF+ melanoma. It is an oral co-pack, avutometinib (RAF/MEK clamp) + defactinib (FAK inhibitor), twice-weekly + twice-daily dosing cycles approved by the US FDA in 2025 and may be accessible to patients in Bangladesh through a Named Patient Program or personal-import pathway.
Access in Bangladesh
Bangladesh's DGDA accepts named-patient import under personal-use exceptions; volume is lower but pathway exists.
How Reserve Meds coordinates access in Bangladesh
- Patient or treating physician submits a request.
- We verify clinical appropriateness and Bangladesh-specific eligibility.
- Treating physician in Bangladesh issues prescription and clinical justification.
- Country-specific NPP/personal-import forms are prepared and filed.
- We source Avmapki Fakzynja Co‑Pack from a DSCSA-compliant US specialty wholesaler.
- Cold-chain shipment to the patient's physician or hospital pharmacy in Bangladesh.
Typical timeline for Bangladesh
End-to-end, most requests are completed in 2-6 weeks. Bangladesh's tier 3 regulatory maturity typically supports longer processing times.
What patients and physicians in Bangladesh ask
- Is the pathway legal in Bangladesh? Yes - it operates under Bangladesh's established NPP or personal-import framework.
- Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
- What physician credentials do I need? A licensed physician in Bangladesh able to issue the prescription and clinical justification.
- What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
- Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.